PAVmed Inc. 2023 Form 10-K Summary
Business context and reporting period
This annual report covers the fiscal year ended December 31, 2023, and was filed March 25, 2024. PAVmed is a multi-product life sciences company whose consolidated results include majority-owned Lucid Diagnostics and Veris Health. Its primary commercial focus is Lucid’s EsoGuard esophageal DNA test, used with the EsoCheck cell-collection device; Veris is pursuing partnerships for its digital oncology-care platform. The company reports as one operating segment.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $2.452 million | $0.377 million |
| Cost of revenue | $6.420 million | $3.614 million |
| Gross loss / gross margin | $3.968 million / approximately -162% | $3.237 million / approximately -859% |
| Operating expenses | $71.247 million | $91.464 million |
| Operating loss | $68.795 million | $91.087 million |
| Net loss before noncontrolling interests | $79.263 million | $103.238 million |
| Net loss attributable to PAVmed common stockholders | $66.270 million | $89.264 million |
| Net loss per share, basic and diluted | $9.16 | $15.03 |
| Cash used in operations | $52.036 million | $70.985 million |
| Cash provided by financing | $31.173 million | $38.211 million |
| Cash at year-end | $19.639 million | $39.744 million |
At December 31, 2023, current assets were $24.498 million and current liabilities were $54.177 million, a working-capital deficit of approximately $29.7 million. Total liabilities were $57.137 million and stockholders’ equity was negative $24.018 million. Consolidated senior secured convertible notes had $37.683 million of face principal and a $44.2 million fair value; the balance sheet classified the $44.2 million fair-value amount as current at year-end. The company also reported $4.525 million of operating lease liabilities.
Material changes versus 2022
- Revenue increased $2.075 million, principally from EsoGuard testing performed in Lucid’s own laboratory. The prior-year figure included revenue under the former ResearchDx commercialization arrangement, terminated in February 2022.
- Operating loss narrowed by $22.292 million. Sales and marketing declined $1.735 million, general and administrative expense declined $10.463 million, and research and development declined $11.062 million; cost of revenue rose $2.806 million.
- Cash used in operations improved by $18.949 million, but year-end cash fell by $20.105 million. Financing included $18.625 million from Lucid preferred-stock issuance and $10.0 million from a Lucid convertible note.
- Other significant 2023 charges included a $6.026 million loss from changes in convertible-note fair value, $3.782 million of debt-extinguishment loss, and a $1.791 million deemed dividend related to extending Series Z warrants. The fair-value debt measurement uses significant Level 3 assumptions; it was the auditor’s critical audit matter.
Outlook, risks, and notable events
Management provided no quantified revenue or earnings guidance. It expects recurring losses and negative operating cash flows, and says continuing operations beyond March 2025 depends on substantially increasing revenue and raising or refinancing capital. The company and its auditor identified substantial doubt about PAVmed’s ability to continue as a going concern. The auditor issued an unqualified opinion on the financial statements with a going-concern explanatory paragraph; management assessed internal control over financial reporting as effective, and the filing did not include an auditor attestation on internal controls.
- Financing and debt: In March 2024, the holder of PAVmed’s April and September 2022 notes extended maturities to April and September 2025 and waived specified financial covenants through August 31, 2024. In exchange, PAVmed agreed to pay $2.0 million by April 25, 2024. The filing describes cash-payment, covenant, refinancing, and dilution risks.
- Reimbursement and regulation: EsoGuard’s Medicare payment determination is $1,938.01, but the company had not obtained a final MolDX coverage determination. The 2023 local coverage policy sets evidence criteria, and Lucid planned to seek technical assessment. FDA proposed phasing out general enforcement discretion for laboratory-developed tests; changes to LDT regulation could affect EsoGuard’s commercialization and regulatory obligations.
- Nasdaq: PAVmed regained compliance with the $1 minimum bid-price rule in January 2024 after a 1-for-15 reverse stock split. Separately, Nasdaq notified the company in March 2024 that its market value of listed securities had been below $35 million; the stated deadline to regain compliance was September 3, 2024.
- Subsequent transactions: Lucid raised gross proceeds of approximately $18.16 million in a March 2024 preferred-stock offering and exchange. PAVmed also received about $4.7 million of intercompany fees and reimbursements in Lucid shares in January 2024, then distributed approximately 3.33 million Lucid shares to PAVmed stockholders in February.
- Commercial execution: EsoGuard revenue remains small relative to operating costs, and commercial success depends on payer coverage, clinical-utility evidence, physician adoption, and direct employer contracting. Veris is seeking academic oncology partnerships; its implantable monitor development is resource-dependent. In March 2024, PAVmed launched PMX with Hatch Medical to advance PortIO, EsoCure, and CarpX, subject to financing.
- Other risks and contingencies: The filing highlights continuing funding needs, competition, potential dilution and loss of control of Lucid, product and regulatory risks, and dependence on a single EsoGuard laboratory. PAVmed reported no pending legal proceeding it considered reasonably likely to have a material impact.
Key facts investors should verify
- Available cash, operating burn, and the amount and timing of financing required to meet obligations through and beyond March 2025.
- Whether the $2.0 million debt-related payment was made by the April 25, 2024 deadline, and the status of note covenants, maturities, and any further waivers or refinancing.
- MolDX’s technical assessment and coverage decision for EsoGuard, commercial payer payment trends, and the effect of final FDA LDT requirements.
- Progress toward Nasdaq’s $35 million market-value requirement by September 3, 2024, and the potential consequences of noncompliance.
- Lucid’s preferred-stock conversion and dividend terms, subsequent share issuances, PAVmed’s remaining ownership and voting control, and dilution from PAVmed’s own securities.